Compare PCRX & FLNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | FLNC |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2010 | 2021 |
| Metric | PCRX | FLNC |
|---|---|---|
| Price | $36.35 | $5.83 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 23 |
| Target Price | ★ $33.57 | $8.95 |
| AVG Volume (30 Days) | 2.1M | ★ 6.0M |
| Earning Date | 11-05-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | $541,533,000.00 | ★ $2,262,830,000.00 |
| Revenue This Year | $3.84 | $6.22 |
| Revenue Next Year | $4.73 | $27.68 |
| P/E Ratio | $191.29 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $5.79 |
| 52 Week High | $36.67 | $33.51 |
| Indicator | PCRX | FLNC |
|---|---|---|
| Relative Strength Index (RSI) | 83.97 | 25.45 |
| Support Level | $21.78 | N/A |
| Resistance Level | N/A | $8.11 |
| Average True Range (ATR) | 0.40 | 0.39 |
| MACD | 0.89 | -0.03 |
| Stochastic Oscillator | 97.44 | 6.25 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.